Search
for
Sort by
Research 901–930 of 1000+
- IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes
- Changes in the proteomic profile of adipose tissue-derived mesenchymal stem cells during passages
- Evaluation of Polyacrylonitrile Nonwoven Mats and Silver–Gold Bimetallic Nanoparticle-Decorated Nonwoven Mats for Potential Promotion of Wound Healing In Vitro and In Vivo and Bone Growth In Vitro
- Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry
- Juniperus sabina L. as a Source of Podophyllotoxins: Extraction Optimization and Anticholinesterase Activities
- Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review
- A Primary Adrenal Non-Hodgkin's Lymphoma Presenting as an Incidental Adrenal Mass
- Shh Gene Regulates the Proliferation and Apoptosis of Dermal Papilla Cells to Affect Its Differential Expression in Secondary Hair Follicle Growth Cycle of Cashmere Goats
- The influence of a biofilm‐dispersing wound gel on the wound healing process
- Identification of an osteopontin-derived peptide that binds neuropilin-1 and activates vascular repair responses and angiogenesis
- Regulatory network of ginsenoside biosynthesis under Ro stress in the hairy roots of Panax ginseng revealed by RNA sequencing
- Therapies and nanotherapies for cervical cancer (Review)
- Weight Changes Are Linked to Adipose Tissue Genes in Overweight Women with Polycystic Ovary Syndrome
- Novel Quinazoline Derivative Induces Differentiation of Keratinocytes and Enhances Skin Barrier Functions against Th2 Cytokine-Mediated Signaling
- Normal-pressure-prepared chitosan carbonate liquid dressing: Spontaneous transformation into a pure chitosan water-resistant film and enhanced wound repair
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
- A Comprehensive Review of Acne Treatments: Unpacking the Chemical Structures and Effective Bioactive Compounds
- Microneedle-Based Technologies for Long-Acting Transdermal Drug Delivery in Wearable Devices
- Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion
- The Trilogy of Skin Regeneration via Metal-Organic Frameworks Nanomedicine: Precision Management of Refractory Wounds, Pathological Scarring, and Hair Follicle Reactivation
- LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties
- SAT368 Severe Hyperandrogenism in a Young Woman with Elevated BMI: A Case Study of The Role of Weight Loss in The Management of PCOS
- Cemiplimab-Induced Alopecia Areata
- The Hair-An Syndrome: A Report of a Misdiagnosed Case with Unfortunate Outcome
- Cosmeceutical and Dermatological Potential of Olive Mill Wastewater: A Sustainable and Eco-Friendly Source of Natural Ingredients
- Recombinant Human Growth Hormone Promotes Burn Wound Repair by Regulating Vascular Endothelial Growth Factor and Micro Vessel Density
- EMT Factors and Metabolic Pathways in Cancer
- Microneedles as transdermal drug delivery system for enhancing skin disease treatment
- Liposomal Packaging Generates Wnt Protein with In Vivo Biological Activity